Literature DB >> 24550423

Prognostic impact of minimal pleural effusion in non-small-cell lung cancer.

Jeong-Seon Ryu1, Hyo Jin Ryu, Si-Nae Lee, Azra Memon, Seul-Ki Lee, Hae-Seong Nam, Hyun-Jung Kim, Kyung-Hee Lee, Jae-Hwa Cho, Seung-Sik Hwang.   

Abstract

PURPOSE: Minimal (< 10 mm thick) pleural effusion (PE) may represent an early phase of malignant PE, but its clinical relevance has rarely been studied. Therefore, we examined the proportion of minimal PE in patients with non-small-cell lung cancer (NSCLC) and its impact on survival. We also considered possible accumulation mechanisms in our data set. PATIENTS AND METHODS: On the basis of PE status from chest computed tomography scans at diagnosis, 2,061 patients were classified into three groups: no PE, minimal PE, and malignant PE. Twenty-one variables associated with four factors-patient, stage migration, tumor, and treatment-were investigated for correlation with survival.
RESULTS: Minimal PE presented in 272 patients (13.2%). Of 2,061 patients, the proportion of each stage was the following: 5.2% stage I, 10.9% stage II, 13.2% stage IIIA, 23.8% stage IIIB, and 13.9% stage IV. Minimal PE correlated significantly with shorter survival time than did no PE (median survival time, 7.7 v 17.7 months; log-rank P < .001), even after full adjustment with all variables (adjusted hazard ratio, 1.40; 95% CI, 1.21 to 1.62). Prognostic impact of minimal PE was higher in early versus advanced stages (Pinteraction = .001). In 237 patients (87.8%) with minimal PE, pleural invasion or attachment as a direct mechanism was observed, and it was an independent factor predicting worse survival (P = .03).
CONCLUSION: Minimal PE is a commonly encountered clinical concern in staging NSCLCs. Its presence is an important prognostic factor of worse survival, especially in early-stage disease.

Entities:  

Mesh:

Year:  2014        PMID: 24550423     DOI: 10.1200/JCO.2013.50.5453

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

Review 1.  Pleural involvement in lung cancer.

Authors:  Theodora Agalioti; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  [Detection of carcinoembryonic antigen levels in pleural effusion and serum and their ratio for differential diagnosis of pleural effusion resulting from tuberculosis and lung cancer].

Authors:  Ruicheng Li; Zhaowei Gao; Ke Dong; Huiping Wang; Huizhong Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-02-28

3.  Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.

Authors:  Zi-Liang Hou; Yu Kang; Guang-Zhong Yang; Zhen Wang; Feng Wang; Yan-Xia Yu; Wen-Ming Chen; Huan-Zhong Shi
Journal:  Ann Hematol       Date:  2021-03-14       Impact factor: 3.673

Review 4.  Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion.

Authors:  Yiran Niu; Qiong Zhou
Journal:  Cell Mol Life Sci       Date:  2022-03-17       Impact factor: 9.261

5.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

6.  Mast cells mediate malignant pleural effusion formation.

Authors:  Anastasios D Giannou; Antonia Marazioti; Magda Spella; Nikolaos I Kanellakis; Hara Apostolopoulou; Ioannis Psallidas; Zeljko M Prijovich; Malamati Vreka; Dimitra E Zazara; Ioannis Lilis; Vassilios Papaleonidopoulos; Chrysoula A Kairi; Alexandra L Patmanidi; Ioanna Giopanou; Nikolitsa Spiropoulou; Vaggelis Harokopos; Vassilis Aidinis; Dionisios Spyratos; Stamatia Teliousi; Helen Papadaki; Stavros Taraviras; Linda A Snyder; Oliver Eickelberg; Dimitrios Kardamakis; Yoichiro Iwakura; Thorsten B Feyerabend; Hans-Reimer Rodewald; Ioannis Kalomenidis; Timothy S Blackwell; Theodora Agalioti; Georgios T Stathopoulos
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

Review 7.  The role of surgical intervention in lung cancer with carcinomatous pleuritis.

Authors:  Takayuki Fukui; Kohei Yokoi
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 8.  Malignant pleural effusion: medical approaches for diagnosis and management.

Authors:  Hae-Seong Nam
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-05-29

9.  Abdominal lymph node metastasis by lymphatic spread through the thoracic duct in patients with non-small-cell lung cancer.

Authors:  Wookyung Ryu; Myoung Kyu Lee; Mi Hwa Park; In Young Hyun; Minkyung Lee; Eun-Ji No; Seok Joong Yong; Jung Soo Kim; Jun Hyeok Lim; Jeong-Seon Ryu
Journal:  Thorac Cancer       Date:  2021-05-25       Impact factor: 3.500

10.  Monoclonal antibody targeting of mononuclear cell chemokines driving malignant pleural effusion.

Authors:  Antonia Marazioti; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2014-06-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.